Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Mar 1.

Published in final edited form as: Mol Cancer Ther. 2010 Feb 9;9(3):558–568. doi: 10.1158/1535-7163.MCT-09-0627

Fig. 1 — A. MLH1-deficient (HCT116+ch2, RKO), MSH2-deficient (Hec59) and matched MLH1-proficient (HCT116+ch3, RKO+MLH1+), MSH2–proficient (Hec59+ch2) cells were either mock (DMSO) treated or exposed to curcumin (Curc; 30 μM) and cell viability was assessed 48 h later by Trypan Blue exclusion. B. Cell lines outlined in panel A were treated with 0, 5, 10 and 20 μM of curcumin and viability was measured by MTT assay. C. Indicated cell lines were exposed to various doses of curcumin (0, 10, 20, 30, 40 and 50 μM), colonies counted 14 days after drug, and subsequently plotted against curcumin concentration. Each point represents the mean value obtained from at least three independent experiments, error bars = 1 SD.

Fig. 1 — A. MLH1-deficient (HCT116+ch2, RKO), MSH2-deficient (Hec59) and matched MLH1-proficient (HCT116+ch3, RKO+MLH1+), MSH2–proficient (Hec59+ch2) cells were either mock (DMSO) treated or exposed to curcumin (Curc; 30 μM) and cell viability was assessed 48 h later by Trypan Blue exclusion. B. Cell lines outlined in panel A were treated with 0, 5, 10 and 20 μM of curcumin and viability was measured by MTT assay. C. Indicated cell lines were exposed to various doses of curcumin (0, 10, 20, 30, 40 and 50 μM), colonies counted 14 days after drug, and subsequently plotted against curcumin concentration. Each point represents the mean value obtained from at least three independent experiments, error bars = 1 SD.